Welcome to the 2nd Annual Dry AMD Therapeutic Development Summit: Uncovering the Largest Untapped Eyecare Market
The Only End-to-End Forum Solely Dedicated to Targeting Inflammatory/Regenerative Pathways Whilst Overcoming Challenges With Drug Delivery, Safety and Validated Endpoints To Bring About Clinically Effective Dry-AMD Therapies
Hybrid Format (Virtual and In-Person: Lisbon, Spain)
–
INAD/PLAN – RT001 Development Efforts and the INAD Rating Scale (INAD-RS)
A phase 2/3 of a study* to evaluate the safety and efficacy of Retrotope’s investigational drug candidate RT001 in patients with INAD is underway. Dr. Paldeep Atwal and Sarah Endemann from Retrotope will be speaking about RT001’s mechanism of action and providing an overview of the clinical trial study design. They will also share information about their INAD prospective natural history study and their efforts to develop the INAD-RS, a novel neurological assessment scale for INAD, that demonstrates strong correlation with disease severity and disease progression.
More details and agenda:
click here
–
Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that Anil Kumar, president and chief business officer, will deliver a corporate presentation as part of the H.C. Wainwright Global Life Sciences Conference. The conference, which will take place March 9-10, 2021, is being conducted with a virtual format.
More details and agenda:
click here
National University of Singapore
Organizer: Prof. Markus R Wenk
Welcome to the 9th international Singapore Lipid Symposium (iSLS9). iSLS has become a regular event in the field of lipid research. We are grateful for your continued support and extend a warm welcome to newcomers.
For more details, click here
Watch recording:
video
Dr Mikhail S. Shchepinov, Retrotope’s CSO, is to present at the 3rd International conference FREE RADICALS IN CHEMISTRY AND LIFE, October 10-11, Minsk, Belarus.